

Argenica Therapeutics with Proactive at the ASX Small and Mid-Cap Conference



NEWS RELEASE BY ARGENICA THERAPEUTICS LTD

Melbourne, Victoria | March 22, 2023 12:50 PM Eastern Daylight Time

Argenica Therapeutics Ltd (ASX: AGN) CEO Liz Dallimore speaks with Proactive from the ASX Small and Mid-Cap Conference March 2023. The company is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Its lead neuroprotective peptide candidate, ARG-007, has been demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).



Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Tags

ARGENICA THERAPEUTICS LTD

BIOTECH

ASX

PROACTIVEAUSTRALIA

PROACTIVEINVESTORS